The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...
The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...
NEW YORK – BeiGene on Wednesday said the European Commission approved the anti-PD-1 monoclonal antibody Tevimbra (tislelizumab) with chemotherapy as a first-line treatment for esophageal squamous cell ...
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
NEW YORK – Anocca said on Tuesday that it is seeking permission from the European Medicines Agency to begin testing its T-cell receptor (TCR) T-cell therapy ANOC-001 in a Phase I/II trial in advanced ...
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
NEW YORK – Ataraxis AI is developing artificial intelligence-driven digital pathology tests that it believes may provide faster, more accurate, and more cost-effective answers to clinical questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback